SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 14, 2003
---------------
CYTOGEN CORPORATION
--------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-14879 22-2322400
---------------------------- ------------------------ -------------------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
650 College Road East, CN 5308, Suite 3100, Princeton, NJ 08540
--------------------------------------------------------- -------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (609) 750-8200
--------------
ITEM 9. REGULATION FD DISCLOSURE (INFORMATION FURNISHED PURSUANT TO ITEM 12,
"DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION").
On August 14, 2003, Cytogen Corporation (the "Company") announced its
financial results for the quarter ended June 30, 2003. The full text of the
press release issued in connection with the announcement is attached as Exhibit
99.1 to this Current Report on Form 8-K.
In accordance with the procedural guidance in SEC Release Nos. 33-8216
and 34-47583, the information in this Form 8-K and the Exhibit attached hereto
is being furnished under "Item 9. Regulation FD Disclosure" rather than under
"Item 12. Disclosure of Results of Operations and Financial Condition." The
information shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a
filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this current report on Form 8-K to be signed on
its behalf by the undersigned hereunto duly authorized.
CYTOGEN CORPORATION
By: /s/ Michael D. Becker
-----------------------------
Michael D. Becker
President and Chief Executive
Officer
Dated: August 14, 2003
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press release dated August14, 2003.